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Aging is a complex process of damage accumulation, and has been viewed as
experimentally and medically intractable. The number of patients with age-associated
diseases such as type 2 diabetes mellitus (T2DM), osteoporosis, Alzheimer’s disease (AD),
Parkinson’s disease, atherosclerosis, and cancer has increased recently. Aging-related
diseases are related to a deficiency of the immune system, which results from an
aged thymus and bone marrow cells. Intra bone marrow-bone marrow transplantation
(IBM-BMT) is a useful method to treat intractable diseases. This review summarizes
findings that IBM-BMT can improve and treat aging-related diseases, including T2DM,
osteoporosis and AD, in animal models.
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INTRODUCTION
Aging is a complex process of damage accumulation, and has
been viewed as experimentally and medically intractable. The
process of aging leads to marked malfunction of multiple cellular
and molecular events that ultimately get translated into various
chronic ailments and diseases such as Type 2 diabetes mellitus
(T2DM), Alzheimer’s disease (AD), and osteoporosis, Parkinson’s
disease, atherosclerosis and cancer (Caruso et al., 2004). In this
review, we summarize the findings in animal model mice treated
with stem cell transplantation for T2DM, osteoporosis and AD.
T2DM is induced by obesity, a sedentary lifestyle and nutri-
tional factors, while there are also genetic factors that appear to
impact the interaction of multiple genes during the development
of T2DM (Adeghate et al., 2006; Ali, 2013). T2DM is not consid-
ered to be an autoimmune disease, but some autoantibodies such
as islet-cell antibodies and glutamic acid decarboxylase antibodies
have been reported to be positive in some young T2DM patients
(Klingensmith et al., 2010). Therapies for T2DM mainly include
lifestyle changes and oral drugs to reduce the hyperglycemia and
improve insulin sensitivity. However, these measures fail to main-
tain blood glucose levels in the normal range all the time. Recent
research into cell based-stem cell therapies has been focused on
T2DM. Osteoporosis is one of the most common bone disorders
and is now classified into primary and secondary types. Though
primary osteoporosis usually occurs in both sexes at all ages, it is
often observed in postmenopausal women and even in men later
in life. A review of current therapies indicates that bisphospho-
nates, anti-receptor activator of NF-kb ligand, and anti-sclerostin
antibodies are used to counter osteoporosis (Das and Crockett,
Abbreviations: AD, Alzheimer’s disease; BM, bone marrow; BMT, bone marrow
transplantation; ESC, embryonic stem cell; IBM-BMT, intra bone marrow-BMT;
iPSCs, pluripotent stem cells; NFAT, nuclear factor of activated T-cell; SAM,
senescence-accelerated mouse; SAMP, SAM-prone; SAMR, SAM-resistant; TECs,
thymic epithelial cells; TRAICR/RANKL, TNF-related activation-induced cytokine
receptor/receptor activator of nuclear factor-kb ligand; TSCs, thymic stroma cells;
STZ, streptozocin; T2DM, Type 2 diabetes mellitus; TT, thymus transplantation.
2013). AD is a kind of neurological disorder that causes a decrease
in cognitive ability, resulting from the deposition of beta-amyloid
plaque, neurofibrillary tangles and neurodegeneration (Mielke
et al., 2014). The role of tau has become the focus of attention in
AD therapy, because current drug treatment using cholinesterase
inhibitors or NMDA antagonists has proven to be only mod-
estly successful (Medina and Avila). Animal models are useful
for basic studies, and the senescence-accelerated mouse (SAM)
strain was established as a novel murine model of senescence
acceleration and age-associated disorders (Takeda, 1999). This
strain includes SAM-prone, short-lived mice (SAMP) and SAM-
resistant, long-lived mice (SAMR). The respective SAMP models,
with their characteristic pathological phenotypes, show similar
age-associated disorders, including osteoporosis and AD, to those
often observed in elderly humans (Takeda, 2009).
AGING IMPAIRS IMMUNE RESPONSE AND THYMUS
It is widely accepted that progression of age is associated with an
increasingly compromised immune system. Age-related hemato-
logic changes are reflected by a decline in bone marrow cellularity
and a declining adaptive immunity (Linton and Dorshkind, 2004;
Hakim and Gress, 2007). Aging is associated with profound alter-
ations in the innate immune system, as exemplified by alterations
in the T cell and B cell compartments, functional decline in the
monocytes and macrophages, low expression of Toll-like recep-
tors from activated splenic and peritoneal macrophages, and an
altered secretion of several chemokines and cytokines (Licastro
et al., 2005). Additionally, aged dendritic cells have been report-
edly found to be less efficient in activating T and B cell popula-
tions (Meydani and Wu, 2007). Key manifestations of changes in
the immune system that progress with age are reduced efficacy of
vaccine-induced protection against infections/diseases and poor
response to new pathogens (Nikolich-Zugich, 2008). Th17+ CD4
cells increased in the aged mice resulting from elevation of IL-
1β expression and the reduction in IL-2 expression in aged mice
(Lim et al., 2014). Restoration of the T-cell population balance
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and numbers has been shown to lead to amarked improvement in
immunogenic response (Haynes et al., 2005). Alterations in B cells
have also been recognized in age-related changes in the immune
system. In elderly humans, peripheral B cell percentages and
numbers are significantly lowered and show decreased humoral
immunity to pathogens and vaccines (Frasca et al., 2008).
The thymus undergoes age-related progressive involution with
decreased thymic lymphopoiesis, reduced thymic size and dis-
rupted thymic architecture (Li et al., 2003). The thymus is mainly
composed of T-cell precursors-thymocytes of hematopoietic ori-
gin and thymic stroma cells (TSCs) of non-hematopoietic origin,
which are primarily thymic epithelial cells (TECs). The thymus,
which is the source of mature T lymphocytes, involutes steadily
with increasing age, which results in a decreased release of new
naïve T cells to the periphery, thereby affecting the adaptive
immunity (Aspinall, 1997). T cell differentiation and repertoire
selection are mediated by specialized cellular microenvironments
provided by the TSC. There are reduced numbers of all thymocyte
subpopulations from early T-cell progenitors to double-negative,
double-positive, CD4 and CD8 single-positive populations with
aging (Heng et al., 2005). Our previous report showed the
existence of donor-type stromal cells in the thymus of mice
was when treated with allogenic bone marrow transplantation
(BMT) plus bones. These findings strongly suggest that stromal
cells can migrate from the bone marrow (BM) to the thymus,
where they participate in the positive selection of thymocytes
(Li et al., 2000).
Donor- derived TECs were found in both the medullary
and the cortical areas of the thymus in MRL/lpr mice treated
with allogenic intra bone marrow-BMT (IBM-BMT, Figure 1).
Furthermore, BM cells contain the precursors of functional TECs,
and they can differentiate into TECs, which results in the correc-
tion of thymic function (Takaki et al., 2008).
STEM CELL THERAPIES FOR T2DM
T2DM shows not only a deficiency in insulin sensitivity but also
reduced beta cell mass, the beta cell mass in T2DM patients
being only 40–60% of the normal level (Guo et al., 2013).
Stem cell therapies for T2DM will likely be a useful approach
in the clinical environment. Hyperglycemia was reversed in
streptozotocin-treated diabetic mice when embryonic stem cell
(ESC)-derived insulin-producing cells were transplanted into
these mice (Raikwar and Zavazava, 2012). Human ESCs effec-
tively differentiated into islet-like cells when exendin-4 was added,
and these insulin producing cells ameliorated hyperglycemia in
NOD/SCID diabetic mice when transplanted into these mice
(Bose et al., 2012). However, there are ethical issues when using
human embryos, and ESC transplants into mouse models can
result in malignant tumors.
Yamanaka’s group was the first to report in 2006 the induce-
ment of pluripotent stem cells (iPSCs) from mouse embryonic or
adult fibroblasts (Takahashi and Yamanaka, 2006). Human iPSCs
were derived from skin cells by retroviral expression of OCT4,
SOX2, c-MYC, and KLF4, and have since been shown to differen-
tiate into functional insulin-producing cells (Tateishi et al., 2008).
iPSCs can differentiate into insulin-producing cells responding
to glucose stimulation, thereby improving the hyperglycemia
FIGURE 1 | Hair on the knee joint was shaved and a 26-gauge needle was
inserted into the bone marrow cavity to make a hole in the bone. A
microsyringe containing the donor BMCs was then inserted and the BMCs
injected via the bone hole into the bone marrow cavity.
in T1DM and T2DM mouse models (Alipio et al., 2010). For
preventing allograft rejection in the clinical setting, iPSCs have
been generated from diabetes patients themselves, including those
with T1DM and T2DM as well as those with other types of dia-
betes such as mature-onset diabetes of the young (Maehr et al.,
2009; Ohmine et al., 2012; Teo et al., 2013).
Autologous BM-derived rat MSCs were expanded in vitro, and
transplanted into rats in which the diabetic state was induced by
streptozocin (STZ). Transplanted MSCs can home to the pan-
creas and promote PDX-1 and insulin expression in the islets to
normalize hyperglycemia, and these MSCs have immunoregula-
tory effects (Boumaza et al., 2009). Human BM-derived MSCs
have been shown to protect human islets from pro-inflammatory
cytokines (Yeung et al., 2012), and to enable MSCs to differen-
tiate into insulin-producing cells in vitro. These cells have been
shown to improve hyperglycemia when transplanted into diabetic
mice (Gabr et al., 2013). Multiple intravenous bone marrow-
derived MSC injections normalized hyperglycemia in rats in
which T2DM was induced by a high fat diet and STZ (Hao et al.,
2013). Human adipose tissue-derivedMSCs also differentiate into
glucose-sensitive insulin-producing cells, which help improve
glucose levels and decrease levels of inflammatory cytokines
and free fatty acids in T2DM mice (Dave et al., 2013; Nam
et al., 2013). Umbilical cord blood-derived-MSCs have also been
shown to differentiate into insulin-producing cells, and these
cells expressed pancreatic beta cell development-related genes.
Moreover, these differentiated insulin-producing cells were able
to alleviate hyperglycemia after being transplanted into diabetic
NODmice (Wang et al., 2011a). Clinical data show that umbilical
cord blood-derived stem cells reverse the immune dysfunction via
the modulation of the immune response in T2DM patients (Zhao
et al., 2013).
We previously described how BM-derived stem cells can ame-
liorate blood glucose levels in KK-Ay mice, a T2DM mouse
model (Li and Ikehara, 2013). We also showed that IBM-BMT
combined with Co (III) Protoporphyrin IX Chloride, which
Frontiers in Cell and Developmental Biology | Stem Cell Treatments May 2014 | Volume 2 | Article 16 | 2
Ikehara and Li Aging-related diseases treated with stem cells
induces HO-1 expression, could eradicate T2DM in an ob/ob
mouse model (Abraham et al., 2008). We used not only IBM-
BMT but also thymus transplantation (TT) to treat the db/db
mouse, another T2DM mouse model, because the db/db mouse
exhibits a marked reduction in the size and cellularity of the
thymus (Kimura et al., 1998). Our results showed that, in this
mouse model, IBM-BMT+TT increased insulin sensitivity and
decreased blood glucose levels resulting from a normalization
of the ratio of CD4/CD8 in the peripheral blood, an increase
in adiponectin levels, and enhanced insulin receptor sensitivity.
IBM-BMT+TT enhanced HO-1 expression and increased AKT
and AMPK expression in the pancreas (Li et al., 2010) and, more-
over, upregulated HO-1, peNOS and pAKT levels in the kidney
of these mice (Li et al., 2012). In T2DM patients, intrapancreatic
autologous stem cell infusion combined with hyperbaric oxygen
treatment may reduce insulin requirements (Estrada et al., 2008)
and the need for oral hypoglycemic drugs (Wang et al., 2011b).
In one report, autologous BMT was shown to decrease insulin
requirements, which correlates with stimulation of C-peptide
in T2DM patients (Bhansali et al., 2013). The report suggested
that the implantation of autologous BM mononuclear cells for
the treatment of T2DM is safe and effective because no side
effects were noted after transplantation. This therapy can partially
restore the function of islet beta-cells and maintain blood glucose
homeostasis over the longer term (Hu et al., 2012).
IBM-BMT PREVENTS AND TREATS OSTEOPOROSIS IN
SAMP6 MICE
SAMP6 is a kind of substrain of SAM that spontaneously
develops osteoporosis early in life and is, therefore, a use-
ful model for examining the mechanisms underlying osteo-
porosis (Chen et al., 2009). IL-6, TNFα and TGFβ might be
involved in osteoporosis through the regulation of osteoblas-
togenesis and osteoclastogenesis. TNFα can stimulate the pro-
duction of IL-6 by osteoblasts (originally derived from stroma
cells), resulting in an augmentation of TNF-related activation-
induced cytokine receptor/receptor activator of nuclear factor-
kb ligand (TRAICR/RANKL), which induces osteoclastogenesis,
whereas TGFα, which is produced by osteoclasts, controls the
osteoblastogenesis of stroma (Mundy et al., 1995; Roggia et al.,
2001). One report has indicated that strontium ranelate acts
on lineage allocation of MSCs by antagonizing the age-related
switch in osteoblasts to adipocyte differentiation via mechanisms
involving the nuclear factor of activated T-cell (NFAT)c/Maf
and Wnt signaling, resulting in increased bone formation and
an attenuation of the bone loss in senescent osteopenic mice
(Saidak et al., 2012). The BM microenvironment was nor-
malized after IBM-BMT. Increased production of IL-11, IL-6,
and Rank L ameliorated the imbalance between bone absorp-
tion and formation, resulting in the prevention of osteoporo-
sis in SAMP6 (Takada et al., 2006; Ueda et al., 2007). It is
accepted that RANKL, RANK, and osteoprotegerin are essen-
tial for controlling the oesteoclast development and functions in
bone remodeling, and inhibition of RANKL activity by osteo-
protegerin injection results in significantly reduced bone loss in
arthritis (Kong et al., 1999) and osteoporosis (Mizuno et al.,
1998).
IBM-BMT AMELIORATES LOSS OF COGNITIVE ABILITY AND
EXPRESSION OF SIRT1 ON TECs IN AD MODEL MICE
SAMP 8 (Butterfield and Poon, 2005) and 10 are two substrains of
SAM that have been extensively used in studies as ADmodel mice.
These mice show age-related deficits in learning and memory
with/without forebrain atrophy and impaired immune response.
HO-1 is a very sensitive marker of oxidative stress, and chronic
over-expression of HO-1 in the AD brain, possibly in response to
excessive amyloid provocation, may account for the (transferrin
receptor-independent) iron overload and mitochondrial insuf-
ficiency observed in this disorder (Schipper, 2000). The higher
oxidative stress status is observed to be partly caused by mito-
chondrial dysfunction in the SAM, resulting in the excessive pro-
duction of reactive oxygen species and neurodegeneration (Chiba
et al., 2009). The SAMP8 is an acceptable rodent model for cogni-
tive deficits observed with aging, such as AD, and is found to have
age-related deficits in learning and memory that could not be
explained in terms of differences in sensorimotor or motivational
capabilities (Flood and Morley, 1992). Moreover, beta-amyloid
has been shown to play a central role in the pathophysiology of
AD through the induction of oxidative stress. One report has
demonstrated that antisense oligonucleotide directed against PS-
1 in old SAMP8mice improved learning andmemory deficits and
reduced beta-amyloid-mediated oxidative stress (Fiorini et al.,
2013). Another report indicated that hydrocotyle sibthorpioides
administration prevented spatial learning and memory decline
by the scavenging of free radicals, up-regulating the activity of
antioxidant enzymes, decreasing the level of beta-amyloid, and
ameliorating dysfunction in synaptic plasticity in SAMP8 mice
(Lin et al., 2013).
BM cells can increase the number of activated microglias that
play a central role as APCs and reduce the amyloid deposit via
phagocytosis of beta-amyloid and thereby prevent the progression
of AD (Simard et al., 2006). Our report suggested that IBM-BMT
normalized levels of HO-1, IL-6, IL-1β and iNOS, and amelio-
rated the impaired cognitive ability of SAMP 8 mice (Li et al.,
2009). Initial clinical trials have suggested that non-steroidal anti-
inflammatory drugs could prevent the development of ADs by
inhibiting the immune response (in t’ Veld et al., 2001).
SAMP10 show age-related behavioral deterioration such as
deficits in learning and memory and emotional disorders (Takeda
et al., 1997). These mice also show age-related changes in the
brain such as brain atrophy, shrinkage and loss of cortical neu-
rons, retraction of cortical neuronal dendrites, loss of dendritic
spines, loss of synapses, impaired learning and memory, depres-
sive behavior, accumulation of neuronal DNA damage, neu-
ronal ubiquitinated inclusions, reduced hippocampal cholinergic
receptors, decreased neurotrophic factors, decreased hippocam-
pal zinc and zinc transporters, increased sphyngomyelinase, and
elevated oxidative-nitrative stress (Shimada and Hasegawa-Ishii,
2011). The decline in learning and memory abilities of SAMP10
has been reported to be caused by a decrease in catecholamine
synthesis in the cerebral cortex with aging (Shimada et al., 1993;
Miyajima et al., 2013). Green tea-catechin intake prevented the
experimental tumor metastasis in aged SAMP10 mice by inhibit-
ing age-related decline in immune surveillance (Shimizu et al.,
2010). One report has suggested that theanine improves the
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FIGURE 2 | This is a summary of this review. IBM-BMT increased insulin
sensitivity by upregulating the expression of HO-1, AKT and AMPK, and
improving T2DM. IBM-BMT also regulated the expression of inflammatory
cytokines, controlled the balance between bone absorption and bone
formation, and improved osteoporosis. Furthermore, IBM-BMT regulated
the expression of HO-1, iNOS and IL-1β, resulting in improved cognitive
ability.
cognitive dysfunction and behavioral depression resulting from
psychosocial stress (Unno et al., 2011).
We found that the percentage of CD4/TNFα T cells in the
spleen of 24-week-old (but not 6-week-old) SAMP10 was sig-
nificantly reduced. The thymus was significantly lighter and the
percentage of CD4+CD8+ was lower in the 24-week-old SAMP10
than 6-week-old SAMP10. Real time PCR analysis showed that
the expression of KGF, Aire and Sirt1 was decreased on the TECs
of 24-week-old SAMP10. However, treatment with IBM-BMT
improved these age-related disorders. Another report examined
the finding that IBM-BMT facilitates the entry of transplanted
BM-derived cells into the brain parenchyma. IBM-BMTmay thus
prove beneficial in the experimental treatment of psychiatric and
neurological diseases (Hasegawa-Ishii et al., 2013).
CONCLUSION AND FUTURE DIRECTION
Immune dysfunction, including defective T cells and B cells
may accelerate the aging process in the diabetic mice and
SAMP mice. IBM-BMT has been shown to be a valuable
strategy for the treatment of aging-related disorders in exper-
imental models of T2DM, osteoporosis and AD (Figure 2).
Future studies will focus on related mechanisms through which
IBM-BMT improves aging-related diseases. Additionally, we will
attempt to determine whether IBM-BMT can prevent or treat
other aging-related diseases such as Parkinson’s disease and
atherosclerosis.
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